These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28277884)

  • 1. Investigational drugs for treatment of juvenile idiopathic arthritis.
    Mauro A; Rigante D; Cimaz R
    Expert Opin Investig Drugs; 2017 Apr; 26(4):381-387. PubMed ID: 28277884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapies for juvenile arthritis: agents in early clinical trials.
    Rosina S; Giancane G; Ruperto N
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1109-1124. PubMed ID: 36066506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis.
    Wulffraat NM
    Expert Opin Drug Saf; 2015; 14(12):1961-7. PubMed ID: 26568054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel treatment options for juvenile idiopathic arthritis.
    Steigerwald KA; Ilowite NT
    Expert Rev Clin Pharmacol; 2015; 8(5):559-73. PubMed ID: 26294075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)].
    Bukovac LT; Vidović M; Lamot L; Perica M; Harjacek M;
    Reumatizam; 2013; 60(1):57-66. PubMed ID: 24003687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab for treating juvenile idiopathic arthritis.
    Turnier JL; Brunner HI
    Expert Opin Biol Ther; 2016; 16(4):559-66. PubMed ID: 26848760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
    Machado SH; Xavier RM
    Expert Opin Drug Saf; 2017 Apr; 16(4):493-500. PubMed ID: 28277841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
    Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current therapy of polyarticular forms of juvenile idiopathic arthritis].
    Hospach A; Rühlmann JM; Weller-Heinemann F
    Z Rheumatol; 2016 Apr; 75(3):284-91. PubMed ID: 27001055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches.
    Zaripova LN; Midgley A; Christmas SE; Beresford MW; Baildam EM; Oldershaw RA
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):135. PubMed ID: 34425842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of methotrexate in children with rheumatic diseases.
    Gutiérrez-Suárez R; Burgos-Vargas R
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S122-7. PubMed ID: 21044445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.
    Lovell DJ; Giannini EH; Reiff AO; Kimura Y; Li S; Hashkes PJ; Wallace CA; Onel KB; Foell D; Wu R; Biedermann S; Hamilton JD; Radin AR
    Arthritis Rheum; 2013 Sep; 65(9):2486-96. PubMed ID: 23754188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.
    Wahezi DM; Ilowite NT
    Expert Opin Pharmacother; 2013 Jun; 14(8):975-89. PubMed ID: 23528005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis.
    Hayward K; Wallace CA
    Arthritis Res Ther; 2009; 11(1):216. PubMed ID: 19291269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.
    Kahn R; Berthold E; Gullstrand B; Schmidt T; Kahn F; Geborek P; Saxne T; Bengtsson AA; Månsson B
    Acta Paediatr; 2016 Apr; 105(4):427-32. PubMed ID: 26707699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing regimen determination for juvenile idiopathic arthritis: a review of studies during drug development.
    Ji P; Chowdhury BA; Yim S; Sahajwalla CG
    J Pharm Sci; 2012 Aug; 101(8):2621-34. PubMed ID: 22653876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.
    Pagnini I; Bertini F; Cimaz R
    Paediatr Drugs; 2016 Apr; 18(2):101-8. PubMed ID: 26939782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New advances in juvenile idiopathic arthritis.
    Huang JL
    Chang Gung Med J; 2012; 35(1):1-14. PubMed ID: 22483423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [BIOLOGIC THERAPY FOR JUVENILE IDIOPATHIC ARTHRITIS].
    Brik R
    Harefuah; 2017 Oct; 156(10):659-662. PubMed ID: 29072387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.